Dr.Datsons Labs Ltd
Dr.Datsons Labs Ltd is an India-based integrated pharmaceutical company. The company is engaged in the manufacturing and marketing capabilities in contract research and manufacturing services, and active pharmaceutical ingredients.
- Market Cap ₹ Cr.
- Current Price ₹ 6.40
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 129
- Dividend Yield 0.00 %
- ROCE 5.03 %
- ROE 0.15 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.05 times its book value
Cons
- Company has low interest coverage ratio.
- Company has high debtors of 319 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|
| 480 | 521 | 421 | |
| 375 | 415 | 364 | |
| Operating Profit | 105 | 106 | 57 |
| OPM % | 22% | 20% | 14% |
| 2 | -40 | 8 | |
| Interest | 29 | 43 | 43 |
| Depreciation | 16 | 20 | 20 |
| Profit before tax | 63 | 3 | 1 |
| Tax % | 35% | 84% | 55% |
| 41 | 0 | 0 | |
| EPS in Rs | 29.52 | 0.31 | 0.15 |
| Dividend Payout % | 0% | 32% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 129% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|
| Equity Capital | 14 | 14 | 32 |
| Reserves | 336 | 295 | 376 |
| 299 | 550 | 495 | |
| 70 | 186 | 361 | |
| Total Liabilities | 718 | 1,045 | 1,263 |
| 214 | 208 | 188 | |
| CWIP | 144 | 164 | 179 |
| Investments | 0 | 0 | 210 |
| 360 | 672 | 686 | |
| Total Assets | 718 | 1,045 | 1,263 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|
| 38 | |||
| -34 | |||
| 205 | |||
| Net Cash Flow | 208 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|
| Debtor Days | 153 | 191 | 319 |
| Inventory Days | 142 | 157 | 194 |
| Days Payable | 41 | 150 | 326 |
| Cash Conversion Cycle | 253 | 198 | 186 |
| Working Capital Days | 228 | 204 | 295 |
| ROCE % | 12% | 5% |
Documents
Announcements
No data available.